| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Vertex Pharmaceuticals Incorporated (VRTX) has 13 insiders with recent SEC Form 4 filings, including 0 buys and 34 sells. VRTX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 133.5K | $60.29M | - | |
| COO | 63.4K | $28.62M | - | |
| VP | 51.1K | $23.07M | - | |
| VP | 42.3K | $19.10M | - | |
| Other | 24.0K | $10.85M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 5, 2022 | Sanna Bastiano | EVP, Cell &Genetic Therapies | Sell | 3,725 | $274.10 | $1,021,004.50 | -2.7% | +7.0% | +19.3% | |
| Apr 1, 2022 | Wagner Charles F Jr50 | EVP &Chief Financial Officer | Sell | 2,582 | $264.76 | $683,601.63 | -1.1% | +5.9% | +18.4% | |
| Mar 31, 2022 | McGlynn Margaret G51 | Director | Sale+OE | 5,000 | $262.27 | $1,311,345.89 | -37.6% | +7.4% | +20.7% | |
| Mar 17, 2022 | Tatsis Ourania48 | EVP, Chief Reg. &Quality Off. | Sell | 2,833 | $250.11 | $708,572.06 | -2.9% | +1.4% | +18.3% | |
| Mar 17, 2022 | Wagner Charles F Jr50 | EVP &Chief Financial Officer | Sell | 3,171 | $250.15 | $793,218.35 | -3.3% | +1.4% | +18.3% | |
| Mar 17, 2022 | Sanna Bastiano | EVP, Cell &Genetic Therapies | Sell | 2,122 | $250.06 | $530,627.32 | -4.2% | +1.4% | +18.3% | |
| Feb 25, 2022 | Tatsis Ourania48 | EVP, Chief Reg. &Quality Off. | Sell | 325 | $230.95 | $75,058.08 | -0.1% | +17.1% | +24.8% | |
| Feb 25, 2022 | Altshuler David48 | EVP, Global Research And CSO | Sell | 7,572 | $230.98 | $1,748,989.52 | -4.7% | +17.1% | +24.8% | |
| Feb 18, 2022 | Altshuler David48 | EVP, Global Research And CSO | Sell | 4,312 | $230.97 | $995,949.18 | -1.7% | +11.3% | +27.9% | |
| Feb 18, 2022 | Tatsis Ourania48 | EVP, Chief Reg. &Quality Off. | Sell | 519 | $231.00 | $119,888.58 | -0.2% | +11.3% | +27.9% |